Literature DB >> 7141199

Plasma pancreatic glucagon in pancreatic and primary diabetes, and liver cirrhosis: application of a correction to the radioimmunoassay for pancreatic glucagon.

N Okumura, T Hayakawa, K Yasui, A Noda, T Kondo, K Otsuka, Y Nimura.   

Abstract

Evidence is present that plasma contains non-specific factors which interfere with the 30K glucagon assays. A correction can be made for these interference factors because the factors can be quantitated following absorption of glucagon with charcoal-dextran. Using a correction factor the range of fasting plasma immunoreactive glucagon (IRG) in 12 totally pancreatectomized patients was below detectable limit. Fasting levels of IRG were determined on the plasma from 25 liver cirrhotics complicated by abnormal GTT, 13 pancreatic diabetics with chronic calcified pancreatitis (CCP), 25 adult-onset primary diabetics and 25 healthy subjects. When all samples were measured using no correction factor, the mean levels of IRG were 358 +/- 24 (mean +/- SE), 170 +/- 26, 178 +/- 16 and 178 +/- 7 pg/ml, respectively. Using a correction factor the mean level of IRG were 177 +/- 26, 16 +/- 4, 39 +/- 9 and 20 +/- 4 pg/ml, respectively. The mean values of the interference factor were not significantly different among all five groups. During an arginine infusion the interference factor remained unchanged despite an increase in IRG. It is available but not always necessary to apply a correction factor for 30K glucagon radioimmunoassay.

Entities:  

Mesh:

Substances:

Year:  1982        PMID: 7141199     DOI: 10.1007/bf02774581

Source DB:  PubMed          Journal:  Gastroenterol Jpn        ISSN: 0435-1339


  14 in total

1.  Glucagon antibodies and their use for immunoassay for glucagon.

Authors:  R H UNGER; A M EISENTRAUT; M S McCALL; S KELLER; H C LANZ; L L MADISON
Journal:  Proc Soc Exp Biol Med       Date:  1959 Oct-Dec

2.  Heterogeneity of plasma immunoreactive glucagon.

Authors:  I Valverde; M L Villanueva
Journal:  Metabolism       Date:  1976-11       Impact factor: 8.694

3.  Presence of glucagon immunoreactivity in the globulin fraction of human plasma ("big plasma glucagon").

Authors:  I Valverde; M L Villanueva; I Lozano; J Marco
Journal:  J Clin Endocrinol Metab       Date:  1974-12       Impact factor: 5.958

4.  Glucagon radioimmunoassay using antiserum 30K: interference by plasma.

Authors:  G C Weir; R C Turner; D B Martin
Journal:  Horm Metab Res       Date:  1973-07       Impact factor: 2.936

5.  Glucagon secretion in four duodenopancreatectomized patients after arginine and glucose load.

Authors:  U Krause; M Thiel; J Beyer; G Mangold; U Cordes
Journal:  Horm Metab Res       Date:  1980-08       Impact factor: 2.936

6.  [Plasma insulin, C-peptide and pancreatic glucagon responses to oral glucose load in chronic liver diseases (author's transl)].

Authors:  N Okumura; T Hayakawa; A Noda; T Kondo; A Sakakibara; N Katada; K Kato; M Takeici
Journal:  Nihon Shokakibyo Gakkai Zasshi       Date:  1982-01

7.  Serum lipids, insulin, and glucagon after portacaval shunt in cirrhosis.

Authors:  J L Shurberg; R H Resnick; R S Koff; E Ros; R A Baum; J A Pallotta
Journal:  Gastroenterology       Date:  1977-02       Impact factor: 22.682

8.  Hyperglucagonemia in cirrhosis: altered secretion and sensitivity to glucagon.

Authors:  R S Sherwin; M Fisher; J Bessoff; N Snyder; R Hendler; H O Conn; P Felig
Journal:  Gastroenterology       Date:  1978-06       Impact factor: 22.682

9.  Glucagon immunoreactivities and amino acid profile in plasma of duodenopancreatectomized patients.

Authors:  W A Muller; M Berger; P Suter; H J Cüppers; J Reiter; T Wyss; P Berchtold; F H Schmidt; J P Assal; A E Renold
Journal:  J Clin Invest       Date:  1979-05       Impact factor: 14.808

10.  [Pancreatic endocrine dysfunction in chronic pancreatitis, with special reference to plasma pancreatic glucagon and insulin responses to oral glucose load].

Authors:  T Hayakawa; A Noda; T Suzuki; I Aoki; J Inoue
Journal:  Nihon Shokakibyo Gakkai Zasshi       Date:  1977-02
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.